Vascular Biology and Metabolism (VAM)

Overview

The Vascular Biology and Metabolism (VAM) area was created to enable a comprehensive, cooperative and multidisciplinary approach to research, development and transference of solutions for a group of diseases that are the leading cause of morbidity and mortality in the world: cardio- and neurovascular diseases, diabetes-metabolic syndrome and kidney failure.

This area also includes a group focused on Ophtalmology research and the Medical Molecular Imaging multidisciplinary group.

Publications

230

total

1,274.219

impact factor

5.542

average impact factor

Director: Anna Rosell Novel

team

zoom

download

In 2017 we have explored predictive clinical and biological factors of small vessel disease progression considering changes in neuroimaging markers and cognition over time and their relation to incident stroke. We have published the results of a multicentric biomarkers study (Stroke-Chip study) and started two new European projects as WP Leaders (PRESTIGE-AF and PROOF, clinical trials), funded by the H2020 program. In Cerebral Amyloidosis we have designed new therapeutic strategies by modifying the periphery/brain balance of specific apolipoproteins, which in addition to their function in the lipid metabolism, might to act as efficient chaperones. As leading Coordinators we have started a multicentric clinical study (SMARRTS-II) on neurorehabilitation and biomarkers of repair (ISCIII-funded). At preclinical level we have developed different strategies to study the mechanisms of ischemic injury/repair, for example, by describing the mouse proteome profile after ischemia by MALDI-Imaging.

49

total

318^.090

impact factor

6^.492

average impact factor

SELECTED ARTICLES

Fernández-de Retana S, Montañola A, Marazuela P, De La Cuesta M, Batlle A, Fatar M, Grudzenski S, Montaner J, Hernández-Guillamon M.
Intravenous treatment with human recombinant ApoA-I Milano reduces beta amyloid cerebral deposition in the APP23 transgenic mouse model of Alzheimer’s disease.
Neurobiol Aging. 2017 Dec; 60:116-128.
IF= 5.117 D1
Charidimou A, Imaizumi T, Moulin S, Biffi A, Samarasekera N, Yakushiji Y, Peeters A, Vandermeeren Y, Laloux P, Baron JC, Hernandez-Guillamon M, Montaner J, Casolla B, Gregoire SM, Kang DW, Kim JS, Naka H, Smith EE, Viswanathan A, Jäger HR, Al-Shahi Salman R, Greenberg SM, Cordonnier C, Werring DJ.
Brain hemorrhage recurrence, small vessel disease type, and cerebral microbleeds: A meta-analysis.
Neurology. 2017 Aug 22; 89(8):820-829.
IF= 8.320, D1
Bustamante A, López-Cancio E, Pich S, Penalba A, Giralt D, García-Berrocoso T, Ferrer-Costa C, Gasull T, Hernández-Pérez M, Millan M, Rubiera M, Cardona P, Cano L, Quesada H, Terceño M, Silva Y, Castellanos M, Garces M, Reverté S, Ustrell X, Marés R, Baiges JJ, Serena J, Rubio F, Salas E, Dávalos A, Montaner J.
Blood Biomarkers for the Early Diagnosis of Stroke: The Stroke-Chip Study.
Stroke. 2017; 48: 2419-2425. doi: 10.1161/STROKEAHA.117.017076.
IF: 6.032, D1
Jiménez-Balado J, Riba-Llena I, Garde E, Valor M, Gutiérrez B, Pujadas F,Delgado P.
Prevalence of hippocampal enlarged perivascular spaces in a sample of patients with hypertension and their relation with vascular risk factors andcognitive function.
J Neurol Neurosurg Psychiatry. 2018 Jan 11, doi: 10.1136/jnnp-2017-316724.
IF=7.349, D1
Dávalos A, Cobo E, Molina CA, Chamorro A, de Miquel MA, Román LS, Serena J, López-Cancio E, Ribó M, Millán M, Urra X, Cardona P, Tomasello A, Castaño C, Blasco J, Aja L, Rubiera M, Gomis M, Renú A, Lara B, Martí-Fàbregas J, Jankowitz B, Cerdà N, Jovin TG;
REVASCAT Trial Investigators. Safety and efficacy of thrombectomy in acute ischaemic stroke (REVASCAT): 1-year follow-up of a randomised open-label trial.
Lancet Neurol. 2017 May;16(5):369-376.
IF=26.284, D1

View all publications

Vascular Biology and Metabolism (VAM)

Overview

Publications

Director: Anna Rosell Novel

Research Areas